Introduction {#Sec1}
============

Although the lymphatic system was first described in the 1600s and is recognized to be important to human health \[[@CR1], [@CR2]\], much remains to be learned about its structure and function in both health and disease. Functions of the lymphatics include immune regulation, protein transport, and fluid homeostasis, which are carried out by a complex network of vessels. The network begins with the initial lymphatic capillaries found in the dermis that drain into larger lymphatic vessels which in turn, propel lymph to lymph nodes through the action of lymphangions, and ends at the subclavian vein where lymph is returned to the blood circulation. Failure of lymphatic vessels to function properly due to a genetic defect, injury, or drug interaction may lead to swelling and edema, that if not resolved, leads to lymphedema, a condition in which fluid retention in the extremities causes chronic edema and pain. Eventual fibrosis of the affected tissue may occur owing in part to the lack of lymphatic protein transport from interstitial tissues.

Human genetic studies have, thus far, revealed three genes linked to congenital lymphedema: VEGFR3 \[[@CR3], [@CR4]\], SOX18 \[[@CR5]\], and FOXC2 \[[@CR6]\]. Animal studies with conditional and total knockout of these and other genes \[[@CR7]--[@CR10]\] have shown they are important for early development, establishment, and maintenance of the lymphatic system. More recent work shows that acquired forms of lymphedema, such as that following cancer nodal staging surgeries, may also be associated with gene susceptibility in humans \[[@CR11]\]. In addition, one of the most common off-target effects of marketed and investigational therapeutics is the edema that can occur due to the decreased transport capacity of the lymphatics, enhanced capillary filtration of the blood vasculature, or a combination of both.

Unfortunately, the lymphatic architecture and function in both humans and mouse models of disease has not been well characterized due to the lack of *in vivo* imaging techniques with sufficient temporal and spatial resolution and with adequate contrast agents (for review, see Ref. \[[@CR12]\]). Currently, the clinical gold standard for lymphatic imaging is lymphoscintigraphy which consists of an intradermal or subcutaneous injection of a radiocolloid contrast agent, typically 99mTc, followed by imaging with a gamma camera. The injection can be painful; imaging is time consuming requiring several minutes to acquire images; the procedure exposes the patient to ionizing radiation; and the images exhibit poor spatial and temporal resolution \[[@CR13], [@CR14]\]. Due to these limitations, other imaging methods including computed tomography \[[@CR15], [@CR16]\] and magnetic resonance \[[@CR17]\] have been investigated for enhanced sensitivity imaging of the lymphatics. Unfortunately, they require potentially painful and damaging cannulation of lymphatic vessels, large amounts of contrast agent, and extensive imaging equipment and instrumentation. Recently, our research team and others (for review, see Ref. \[[@CR18]\]) have demonstrated clinical, noninvasive, near-infrared (NIR) fluorescence imaging of human lymphatics using the tricarbocynanine dye, indocyanine green (ICG), and comparatively compact NIR imaging instrumentation. NIR fluorescence with excitation at \>750 nm is advantageous for deep tissue imaging owing to a high signal-to-noise ratio, minimal light absorption, maximal tissue penetration, and low background due to minimal autofluorescence. ICG has maximal absorption at \~780 nm and is approved for clinical use in vascular and hepatic function testing on the basis of its dark green color \[[@CR19]\] and its ability to associate with albumin \[[@CR20]\]. Upon properly designing instrumentation for sensitive collection of its fluorescence, we have performed investigational human lymphatic imaging with rapid image acquisition (200--800 ms) under conditions of ICG microdosing after intradermal injections of as little as 25 μg \[[@CR21]--[@CR26]\]. Furthermore, lymphatic phenotyping of disease on the basis of vessel architecture and function has also been demonstrated using this method \[[@CR25]\].

Although ICG is retained in the lymphatics due to its association with serum proteins, it is an unstable fluorophore requiring its use within hours of reconstitution in saline. A detailed study of degradation kinetics showed that under aqueous conditions, ICG degrades with first-order kinetics. Under the most favorable conditions of darkness and at low temperature (8°C), the half life of ICG was approximately 20 h \[[@CR27]\]. Exposure to light and increased temperature further accelerated the degradation of ICG. The intensity and wavelength of light also significantly impacted the degradation time. Interestingly, ICG exposure to light at 786 nm, (which is the wavelength used by our camera systems), caused faster degradation and a minimal half life of only 2.3 h \[[@CR27]\]. An additional HPLC degradation study of ICG in saline showed that by 25 h a 100 μg/mL solution of ICG had a 70% degradation peak with only 30% of the ICG peak remaining ([Electronic Supplementary Materials](#MOESM1){ref-type="media"}). The rapid appearance of degradation products makes ICG less favorable as a clinically acceptable fluorophore than newly available, more stable fluorophores. These alterations of the fluorescent properties of ICG result in a dim signal, and impair the visualization of deep lymphatic structures such as the saphenous lymphatic channel of the lower leg. Increasing the concentration of ICG leads to a gradual decline in fluorescence intensity \[[@CR27]\], which arises due to stacking of dye molecules and resultant quenching which has been described previously \[[@CR28], [@CR29]\].

Herein, we present our work to develop a brighter, but low molecular weight NIR fluorescent conjugate that is capable of deep tissue lymphatic imaging while also associating with plasma proteins for retention within vascular spaces. The use of plasma proteins such as albumin has recently become a popular strategy for improving the pharmacokinetics and decreasing the clearance of therapeutics targeted to a variety of diseases including arthritis \[[@CR30]\], HIV \[[@CR31]\], and many types of cancer \[[@CR32]--[@CR36]\]. These strategies often take advantage of the fact that due to increased metabolic activity and enhanced permeability of the blood vasculature of tumors and inflammatory tissue, there is an increased uptake and accumulation of serum proteins in these tissues. Furthermore, a lack or impairment of lymphatic vasculature around the tumor may cause a further increase of protein. Application of albumin binding strategies has shown efficacy *in vitro* and also in several animal models, for summary see Table [1](#Tab1){ref-type="table"} \[[@CR37]--[@CR50]\]. Half-life extension methods have included the development of a maleimide derivative of doxorubicin conjugated to albumin, which covalently binds to the free thiol group of cysteine-34 on the albumin protein. As cysteine-34 is unique to albumin, this protein marker provides a general strategy for increasing retention time of therapeutic conjugates of maleimide derivatives by their direct binding to endogenous albumin \[[@CR37]\]. While the endogenous albumin strategy is primarily useful for maleimides, after investigating several half-life extension strategies including pegylation, *N*-glycosylation, and HSA fusion, Linhult and Johansson \[[@CR38], [@CR39]\], identified an albumin-binding domain (ABD) from the bacterial protein Streptococcal G that was able to bind with nanomolar to fentomolar affinity for albumin. They conjugated this ABD to antibody fragments including a Fab and single-chain diabody (scDb). The scDb-ABD was found to have a 10-fold increased half life and higher accumulation in CEA-positive tumors and be favorable for tumor therapy while significantly reducing molecular weight compared with direct antibody fusion methods. In a related approach, in 2002 Dennis *et al.* \[[@CR40]\] used phage display to isolate several peptides that bound with high affinity to serum albumin of multiple species and which could potentially be conjugated to a variety of ligands using *N*-hydroxysuccinimide (NHS) ester chemistry. Mutational analysis and binding studies showed that several serum albumin (SA) peptides were capable of binding with nanomolar affinity and upon conjugation to a Fab fragment were able to extend plasma half-life 25--58-fold thereby increasing therapeutic efficacy. Specifically, one peptide, SA21 showed a high affinity for albumin at a site distinct from albumin's other important ligand binding sites and stability in serum while also maintaining the ability of the Fab to bind tissue factor *in vivo*. Thus, this approach provides a novel method of association to albumin that can be useful for enhancing vascular retention. Table 1Summary of albumin binding strategiesReferenceSummaryMW (KD)Binding affinityKratz el al. \[[@CR37]\]Maleimide derivative of doxorubicin allows for endogenous albumin binding and shows anti-tumor efficacy in breast cancer/leukemia cells67IC~50~ (HSA) = 0.1--1 uMLinhult et al. \[[@CR38]\]Mutational analysis of interaction between albumin binding domain from streptococcal G protein and serum albumin.3Kd (HSA) = 50--1000 nMJohansson et al. \[[@CR39]\]Assessment of structure and binding specificity of G148-4A3 bacterial albumin binding modules.5Kd (HSA/MSA) = 1.6 nM/10.2 nMDennis et al. \[[@CR40]\]Identification of several albumin binding peptides as a strategy for improving pharmacokinetics of proteins.3Kd (HSA) = 467--878 nMIC~50~ (MSA) = 5--12 nMNguyen et al. \[[@CR41]\]Albumin binding Fabs derived from Herceptin; reduction in albumin affinity decreased half-life, increased clearance.3Kd (HSA/MSA) = 556 nM/44--2,500 nMStork et al. \[[@CR42]\]Fusion of bispecific single-chain diabody with albumin-binding domain from streptococcal protein G, increased half-life 5--6 fold.59Kd (HSA/MSA) = 3.4 nM/4.4 nMMuller et al. \[[@CR43]\]Recombinant bispecific antibody molecule fused to albumin increased half-life and enhanced tumor targeting abilities.104--120None reportedAnhorn et al. \[[@CR44]\]Specific targeting of Her2 overexpressing breast cancer cells with HSA nanoparticles covalently attached to trastuzumab, showed enhanced cellular binding and uptake of NP and high cytotoxicity.n/an/aJonsson et al. \[[@CR45]\]Engineering of high affinity HSA binding protein (ABD035) which displayed favorable thermal properties and retained selectivity.5Kd (HSA) = 50--500 fMTrussel et al. \[[@CR46]\]Tumor-targeting, recombinant antibody F8 with albu-tag, conferred high-affinity binding to albumin, \~10-fold increase in tumor uptake25--26Kd (HSA) = 108--307 nMHopp et al. \[[@CR47]\]Effects of affinity and valency of albumin binding domain on half-life.60Kd (HSA/MSA) = 11.2 nM/21.4 nMSebak et al. \[[@CR48]\]In vitro binding study shows efficacy of human serum albumin nanoparticles for drug delivery of noscapine in breast cancer.67None reportedVandoorne et al. \[[@CR49]\]Summary of use of nuclear labeled serum albumin for study of vascular permeability and drainage. (Review)n/an/aAndersen et al. \[[@CR50]\]Half-life extension by indirect targeting of the neonatal Fc receptor (FcRN) using a minimal albumin domain.5Kd (HSA) = 0.1 nM

We have employed a cyclic version of SA21, and we term the cyclic albumin-binding domain (cABD) peptide. We have conjugated the stable, cABD peptide, with a bright NIR fluorophore, IRDye800CW, which itself has favorable clearance, safety, and toxicity profiles \[[@CR51]\]. The chemical structure of cABD-IRDye800 is shown in Fig. [1](#Fig1){ref-type="fig"}. We have also characterized and demonstrated the superiority of cABD-IRDye800 compared with ICG in studies of mouse lymphatics. The use of cABD-IRDye800 as a NIR imaging agent will enable a better understanding of lymphatic vasculature, help elucidate the pathophysiology of lymphatic disease, and provide insight into other diseases in which the lymphatic system may play a role. Fig. 1A chemical structure diagram showing cABD-IRDye800 including the specific site of conjugation and formation of an amide bond between the free amine in the terminal lysine side chain of the cABD peptide and the NHS ester reactive site of IRDye800 CW. The S--S, disulfide bond was added to stabilize the peptide and maintain uniform product once conjugated to IRDye800.

Materials and Methods {#Sec2}
=====================

Agent Preparation {#Sec3}
-----------------

ICG was obtained from Akorn (Lake Forest, IL), stored at room temperature and reconstituted in sterile phosphate-buffered saline (PBS) immediately prior to use. IRDye^®^800CW NHS ester was purchased from LI-COR Biosciences (Lincoln, NE) and reconstituted in PBS or dimethyl sulfoxide (DMSO) prior to use. The cABD peptide, RLIEDICLPRWGCLWEDDK, with disulfide bond between Cys7 and Cys13, \>95% purity, was obtained from Bachem (Torrance, CA), stored as received at −20°C, and reconstituted immediately before use in Sorenson's phosphate buffer (pH 8--8.5). cABD peptide conjugation to IRDye800 was performed by combining equimolar amounts of IRDye800 in DMSO and cABD peptide in phosphate buffer. The specific conjugation reaction occurs by formation of a stable amide bond between the free amine on the terminal lysine of the cABD peptide and the NHS ester reactive group on IRDye800. Although it may appear there are two potential reactive sites on the peptide: (1) the terminal lysine and (2) the terminal NH2 group; the terminal NH2 on the peptide is an amide, and is therefore, unreactive (Fig. [1](#Fig1){ref-type="fig"}). Conjugation occurred overnight at 4°C on a rotator platform under dark conditions. The conjugated cABD peptide was successfully purified using a semi-prep HPLC system equipped with a Zorbax column (C-18, 250 × 10 mm) using a mobile phase of 0.1% TFA in H~2~O/0.1% TFA in CH~3~CN gradient and flow rate of 1 mL/min. A retention time of 32.3 min was measured using EzChrome Elite software. The conjugate was then dried using a vacuum evaporator (Thermo Scientific Inc.) to remove water and residual TFA and stored at −20°C protected from light.

Characterization of Fluorophores {#Sec4}
--------------------------------

Fluorescence optical properties of the fluorophores were determined using the Fluorolog Tau-3 Spectrofluorometer (Horiba Jobin Yvon, Edison, NJ) and absorbance was recorded using the DU-800 Spectrophotometer (Beckman Coulter, Brea CA). All measurements were taken at fluorophore concentrations ≤1 μM. At this low concentration, confounding effects such as quenching of ICG are avoided and fluorophores are more easily compared. In addition, each fluorophore was purified by lyophilization to remove TFA or solvent, prior to being measured to the nearest microgram and prepared at the desired concentration by dilution in the appropriate solvent. Molecular weights (MW) for ICG and IRDye800 were confirmed by the respective vendors and cABD-IRDye800 MW was confirmed by mass spectrometry. Consistency in the preparation methods for each fluorophore also helped ensure accuracy in the final concentration of each fluorophore used to record optical properties and in the event of any minor solvent or salt effects, these would be similar among all fluorophores. Excitation and emission spectra of 1 μM solutions of ICG, IRDye800 and cABD-IRDye800 were obtained at wavelengths of 785 and 830 nm respectively, with an integration time of 0.3 s. Extinction coefficients were determined from the slope of absorbance at 785 nm as a function of the concentration of serial dilutions of each agent at concentrations of 0.01, 0.1, 0.5, and 1 μM. Fluorescence quantum yield was determined by the comparative method of Williams *et al.* \[[@CR52]\] using the quantum yield of ICG (in water) at 785/830 nm \[[@CR53]\] as a reference standard in which fluorescence of each fluorophore at the above-mentioned concentrations was plotted as a function of absorbance. The gradient of this plot and that of the ICG reference standard was then used to calculate quantum yield using Williams' equation \[[@CR52]\]. Frequency domain lifetime measurements were acquired using 1 μM concentrations of each fluorophore over ten frequencies between 20 and 200 MHz, with an excitation and emission of 785 and 830 nm, respectively, and integration time of 12 s. ICG, with known lifetime 0.56 ns \[[@CR53]\] was used as a reference standard.

Mass spectrometry was performed by the Mass Spectrometry Laboratory in the Pharmaceutical Development Center of the Department of Experimental Therapeutics at the University of Texas MD Anderson Cancer Center in Houston TX. The lyophilized cABD-IRDye800 conjugate was dissolved in 80:20 methanol/0.2% formic acid aqueous (pH 3.0) at a concentration of 1 μg/mL. This solution was directly infused into a Waters Quattro ZQ single quadrupole mass spectrometer, operated in electrospray-positive ionization and full scan mode. The confirmation of the molecular weight was done by application of deconvolution software, Waters MaxEnt 3.

An HPLC stability study was performed over 15 days under four storage conditions: water at room temperature or 4°C and PBS at room temperature or 4°C. Stability was assessed by an analytical HPLC system equipped with a Hitachi LaChrom Ultra column (C-18, 5 μm, 4.6 × 150 mm) using a mobile phase of 0.1% TFA in H~2~O/0.1% TFA in CH~3~CN gradient and flow rate of 1 mL/min over 60 min. The percent area of the conjugate peak at a retention time of 24.9 min, Fig. [2](#Fig2){ref-type="fig"}, was used to determine the purity and stability of the cyclic conjugate. Stability was measured at day 0, 1, 2, 3, 4, 7, and 15. Fig. 2HPLC chromatogram showing the cABD-IRDye800 peptide conjugate peak that was eluted from a Zorbax semi-prep C-18A column at 25 min with 95% purity. The unconjugated (free) peptide and cABD-IRDye800 conjugate can be seen as separate peaks in the 280 nm channel.

The IC~50~ of cABD-IRDye800 was determined using a competitive binding assay modified from Dennis *et al.* \[[@CR40]\]. Briefly, Maxisorp fluorescent plates (Nunc, Rochester, NY) were coated with mouse serum albumin (Sigma, St Louis, MO) and incubated overnight at 4°C. Plates were washed with PBS + 0.05% Tween20 (Sigma, St. Louis, MO) to remove unbound albumin and were then blocked with TBS in casein (Pierce, Rockford, IL) for 1 h at 25°C. Equimolar amounts of unconjugated peptide and peptide conjugate were combined in centrifuge tubes for five different concentrations (0--50 nM) of cABD peptide. The resulting peptide solution was then plated on the albumin coated plate, covered, and incubated for 1--2 h at room temperature. The plate was washed with PBS with 0.05% Tween20 to remove unbound peptide, followed by fluorescence imaging at 800 nm on an Odyssey^®^ Infrared Imager (LI-COR^®^ Biosciences, Lincoln, NE). The average and standard deviation of four IC~50~ values were determined.

Affinity measurements were obtained via SPR using a BIACORE T100 (GE Healthcare) instrument similar to a work previously described \[[@CR40]\]. We coupled ≈900 response units of MSA to a CM5 chip using standard NHS-EDC chemistry. A reference flow cell was inactivated for in-line subtraction. Kinetic analysis was performed at 25°C in HEPES-buffered saline EP+ buffer (GE Healthcare) at a flow rate of 60 μl/min. Five 2-fold dilutions of each peptide beginning at 500 nM were analyzed in duplicate, injected over the flow cells for 1 min and dissociation monitored for 5 min. The surface was regenerated with glycine 3.0 and allowed to stabilize 30 s prior to subsequent injections. BIA evaluation software was used to determine Kd using a 1:1 binding model. Affinities provided were the average of three independent experiments for each peptide dilution series with standard deviation recorded.

To confirm binding specificity of the conjugate, a 0.2 mg/mL solution of cyclic peptide was incubated with an equimolar concentration of MSA or ovalbumin (OVA) or 5% human serum for 1 h at room temperature. The cyclic peptide conjugate, MSA, OVA, and free IRDye800 were separated using sodium dodecyl sulfate-polyacrilamide gel electrophoresis (SDS-PAGE). Pre-cast 4--20% long life gels (NuSep, Lawrenceville GA), were run using 1× Tris/Hepes/SDS running buffer for 1--1.5 h at 100 V, followed by fluorescence imaging at 800 nm on an Odyssey NIR imager, at an intensity of 1.5 and focus offset of 3 mm. Gels were then stained with Biosafe Coomassie Blue (BioRad, Hercules CA) overnight at 4°C, to elucidate protein bands, and imaged using an Alpha Innotech gel imaging system (Cell Biosciences, Santa Clara CA). Similarly, to assess albumin binding of ICG and IRDye800, equimolar amounts of ICG and IRDye800, were each incubated with 0.2 mg/mL MSA or 5% human serum. SDS-PAGE was performed as described above, followed by fluorescence imaging at 800 nm using the Odyssey NIR imager. Gels were stained with coomassie blue overnight at 4°C, to elucidate protein bands, and imaged using the Alpha Innotech gel imaging system.

Measurement of Partition Coefficients {#Sec5}
-------------------------------------

The lipophilicity of cABD-IRDye800 was assessed by determination of the water-octanol partition coefficient. 1-Octanol (1 mL) was added to a solution of approximately 40--50 μg of cABD-IRDye800 in water (1 mL), and the layers were vigorously vortexed for 5 min at room temperature and again mixed after 2 h for 3 min. The tubes were centrifuged at 14,000 rpm for 5 min. Three samples of each layer were analyzed spectrophotometrically using the DU-800 Spectrophotometer (Beckman Coulter, Brea CA), applying this formula: $$\documentclass[12pt]{minimal}
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The partition coefficient was determined by calculating the ratio of concentration in octanol/concentration in water and expressed as Log*P*. At least three independent experiments were performed in triplicate to give the mean Log*P* value.

*In Vivo* Studies {#Sec6}
-----------------

All animal studies were approved by the University of Texas Health Science Center Houston, Center for Laboratory Animal Medicine and Care (CLAMC) animal welfare committee. Mice were housed in the university's AAALAC accredited facilities under sterile conditions according to CLAMC policy. Animal studies were conducted using shaved 6--7-week-old female, C57BL/6 mice (Harlan, Charles River). Mice were divided into experimental groups, anesthetized with isofluorane inhalation, 2--3% until unresponsive to painful stimuli and placed on a heating pad to maintain body temperature at 37° during each imaging session (\~30 min/animal). Mice were closely monitored during and after imaging for any adverse events, of which there were none. Each mouse was injected intradermally at the base of the tail with 20 μL of 500 μM ICG, or 20 μL of 100 μM cABD-IRDye800, in order to assess the performance of each fluorophore *in vivo.* The injections were all made by the same investigator (C. D-V) and the injection site was covered with sterile tape immediately prior to imaging to block injection site fluorescence and prevent camera saturation. Figure [3](#Fig3){ref-type="fig"} is a fluorescent image superimposed on a white-light image showing a typical view of normal murine lymphatic vasculature after injection of NIR fluorophore cABD-IRDye800 at the base of the mouse tail. Labels are included to orient the reader and highlight pertinent parameters including, injection site, a lymphatic vessel and inguinal lymph node. Animals were illuminated by a laser diode (100 mA and 80 mW for 785 nm, Sanyo; Richmond, IN) with the light source expanded to a uniform circular area approximately 8 cm in diameter. Fluorescence emission was collected using an EMCCD camera with a holographic notch-plus band-rejection filter (785-nm center wavelength for ICG) and a bandpass filter (830-nm center wavelength for ICG) placed prior to the lens to reject backscattered and reflected excitation light. Fluorescence images were acquired with an integration time of 200 ms. For registration purposes, "white-light" images were taken by removing the filters and acquiring images over 500-ms integration time. Up to 750 fluorescent images and three white-light images were acquired immediately after injection on the left and right side of each animal. Statistical analyses of differences in fluorescent intensity between the agents at each time point were assessed by analysis of variance (ANOVA) and Student's *t* test in which *α* = 0.05. Fig. 3An example of normal murine lymphatic vasculature as typically seen after injection of 20 μL of 200 μM cABD-IRDye800 at the base of the tail, a near-infrared fluorescence image is overlaid on a white-light image to aid in reader orientation, pertinent parameters including injection site, lymph vessel, and inguinal lymph node are denoted.

Lymphatic Clearance {#Sec7}
-------------------

C57/Bl6 mice were anesthetized using 2--3% isoflurane during the induction phase and minimal \<1% isoflurane during the duration of the experiment which lasted 50 min. Mice were maintained at 37° using a heating pad or lamp. Anesthetized mice were intradermally injected with ICG (*n* = 5), IRDye800 (*n* = 4), and cABD-IRDye800, (*n* = 3), using a 31-gauge needle. To quantify lymphatic clearance of each agent, the fluorescence intensity within the region near the inguinal lymph node was recorded at five time points: 0.5, 2.5, 15, 30, and 50 min after injection of each NIR agent. To account for differences in fluorescent intensity, 20 μL of 500 μM ICG or 20 μL of 100 μM of IRDye800 and cABD-IRDye800 were administered to each mouse and fluorescence images (200 ms/frame), were acquired immediately afterward and at each successive time point using the camera system described above. Seven hundred fifty images were taken for the first time point and 200 images for each successive time point. Images were processed using V++ software (Digital Optics; Auckland, New Zealand), and data were analyzed to determine *in vivo* fluorescent intensities in select ROI using ImageJ (NIH, Bethesda, MD) and Matlab (The Mathworks). Fluorescence was normalized to the maximum fluorescence intensity within the inguinal lymph node for each agent and plotted as a function of time. Statistical analysis of the data were conducted using a Student's *t* test with *α* = 0.05.

Results {#Sec8}
=======

Characterization of Imaging Agents {#Sec9}
----------------------------------

Table [2](#Tab2){ref-type="table"} lists the MW, extinction coefficient at 785 nm, quantum yield at 785/830 (Ex/Em), and lifetime for ICG, IRDye800CW, cABD-IRDye800 at 785/830 (Ex/Em). In addition, Table [2](#Tab2){ref-type="table"} also lists the brightness of IRDye800 and cABD-IRDye800 relative to ICG which was computed by taking the ratio of ((extinction coefficient) × (quantum yield))/(extinction coefficient of ICG) × (quantum yield of ICG)). The results showed that IRDye800 itself was approximately five times brighter than ICG, and that on a molar basis the IRDye800 conjugate retained its brightness over ICG. cABD-IRDye800 was 5.6 times brighter and had 1.6 times longer lifetime than ICG. In addition, the lifetime of IRDye800 and cABD-IRDye800 were similar to one another, indicating IRDye800 is a consistent fluorophore when conjugated onto the cABD peptide. Table 2Table of optical properties for NIR fluorophoresAgentMWExtinction coefficient^a^ (M cm)^−1^Quantum yield^b^Lifetime^b^ (ns)Relative brightness vs. ICGICG775103,502 ± 1.1E40.016^c^0.56^c^1IRDye8001,166178,378 ± 7.1E20.046 ± 3.12E−40.93 ± 0.0754.9cABD-IRDye8003,401171,025 ± 1.4E40.054 ± 9.28E−40.92 ± 0.1025.6^a^Absorbance, *λ* = 785 nm^b^Excitation/emission, *λ* = 785/830 nm^c^See Ref. \[[@CR30]\]

Mass spectrometry confirmed that the deconvoluted molecular weight of the cABD-IRDye800 conjugate was 3,401 Da which was in agreement with the expected molecular weight of 3,404 Da based on the sum of the known molecular weights of the cABD peptide and IRDye800. A subsequent HPLC stability study showed that the cABD peptide conjugate remained stable in PBS or water, at both room temperature and 4°C, through day 15 post-conjugation. Percent purity of the conjugate immediately after HPLC purification, for each storage condition ranged between peak areas of 92--98%. The conjugate peaks were maintained within a few percent of this initial area over the study period with the exception of water at room temperature for which one sample had a slightly decreased peak area of about 75%.

Affinity for Serum Protein {#Sec10}
--------------------------

The affinity of the conjugate for albumin was tested by comparing its IC~50~ and Kd for MSA to that reported by Dennis *et al.* for the peptide alone \[[@CR40]\]. We found the purified cyclic peptide conjugate had an IC~50~ of 44.83 ± 4.85 nM. Kd was assessed by surface plasmon resonance and the Kd of the unconjugated cABD peptide was found to be 65 ± 10 nM. While measuring the Kd of cABD-IRDye800, interference between the 760 nm light source of the BIAcore and the peak excitation wavelength of IRDye800 (\~774 nm), possibly caused a recently described phenomenon known as surface plasmon-coupled emission resonance \[[@CR54]\], which inverted the time response curve, and the Kd could not be determined. Therefore, the Kd of cABD conjugated to Dylight680, a spectrally and structurally similar near-infrared dye, was used to confirm conjugate binding to MSA. The Kd of cABD-Dylight680 was 32 ± 5 nM. The sensograms of cABD-Dylight680 and cABD-IRDye800 showed a similar pattern of binding indicating a constant angle of refraction with only changes due to reduction of signal intensity due to absorbance by the fluorophore.

Sodium Dodecyl Sulfate-Polyacrilamide Gel Electrophoresis {#Sec11}
---------------------------------------------------------

Binding specificity of peptide conjugate was assessed using SDS-PAGE. MSA was the positive control for peptide binding, while ovalbumin, a structurally distinct form of albumin was used as a negative control. The NIR fluorescence image in Fig. [4](#Fig4){ref-type="fig"}a shows that a fluorescent band was found only in the samples in which MSA or human serum (but not OVA) was incubated with cABD-IRDye800. This fluorescent band migrated to \~70 kD, which is the approximate molecular weight of cABD-IRDye800 bound to albumin, thus confirming binding. Figure [4](#Fig4){ref-type="fig"}b is the corresponding coomassie protein stained image of the gel which shows, the conjugate bound to MSA (70 kD), MSA (67 kD), and OVA (48 kD), at their expected molecular weights and shows the bands of the human serum proteins as well. The result that the cABD conjugate bound to MSA but did not bind to ovalbumin confirms the specificity of the interaction between the cABD peptide conjugate and MSA. Furthermore, the albumin binding capabilities of ICG and IRDye800 were assessed by incubating both fluorophores in MSA or 10% human serum. ICG showed binding in both MSA, as was seen by the \~68 kD fluorescent band in Fig. [5a](#Fig5){ref-type="fig"}, and serum solution; while IRDye800 appeared to bind to MSA but not human serum. This result suggests that IRDye800 may be binding too weakly to be detected in human serum. The corresponding protein image is shown in Fig. [5b](#Fig5){ref-type="fig"}. Fig. 4SDS-PAGE shows **a** fluorescence and **b** protein images of cABD-IRDye800 after incubation with MSA or OVA, showing specificity of the conjugate for MSA.Fig. 5SDS-PAGE shows **a** fluorescence and **b** protein images of ICG and IRDye800 after incubation with MSA and human serum, showing ICG binds to both, while IRDye800 may only bind MSA.

Partition Coefficients {#Sec12}
----------------------

In order to assess possible differences in hydrophobicity that may impact binding to albumin, the partition coefficients of ICG, IRDye800 and cABD-IRDye800 as determined from the ratio of each fluorophores' concentration in octanol and water were measured and expressed as Log*P* values. There was a small but significant difference (*p* \< 0.05 by ANOVA), in the Log*P* values between the fluorophores, with IRDye800 having the smallest Log*P*, −1.13 +/− 0.08 indicating the greatest concentration of fluorophore in the aqueous phase followed by ICG, −0.69 +/− 0.03 and then cABD-IRDye800, −0.53 +/− 0.005.

*In Vivo* Lymphatic Imaging Studies {#Sec13}
-----------------------------------

Figure [6](#Fig6){ref-type="fig"} shows NIR fluorescence images of the dorsal lateral side of mice injected with 20 μL of (a) 500 μM ICG or (b) 100 μM of cABD-IRDye800. Similarly to ICG, the peptide conjugate was visible in the lower trunk region as well as the inguinal lymph node and the collecting lymphatic vessels leading up to the axillary lymph node. These results indicate the conjugate is able to be taken up, traffic through the lymphatic vasculature and discern key lymphatic features at concentrations lower than that of ICG. Fig. 6Comparative near-infrared fluorescence imaging of normal C57Bl/6 mice injected at the base of the tail with 20 μL of **a** 500 μM ICG or **b** 100 μM cABD-IRDye800, showing visualization of the initial superficial lymphatic vasculature, the inguinal lymph node and a conducting lymphatic vessel leading from the inguinal to axillary node. Imaging reveals ability of the peptide conjugate to provide comparable imaging quality at a lower dose than ICG.

Lymphatic Clearance Study {#Sec14}
-------------------------

The lymphatic clearance of ICG, IRDye800, and cABD-IRDye800 from the inguinal lymph node was investigated by measuring the fluorescence intensities within the node at given intervals between 0 and 50 min. Fluorescent intensities for each fluorophore were normalized to the maximal fluorescence intensity due to variations in absolute fluorescent counts measured within each region of interest surrounding the inguinal lymph node. An assessment of the percent of the maximal total fluorescence at each time point not only provided a measure of the clearance rate of the dye from the lymphatics, but also showed the relative rate of fluorophore entry and exit from the node. cABD-IRDye800 entered the node more rapidly, as by 2.5 min the fluorophore had already reached its maximal fluorescence while ICG did not reach maximum until 15 min. Conversely, the IRDye800 cleared rapidly, while ICG and cABD-IRDye800 retained at least 80% of the maximal fluorescence intensity over the study period. (Normalization is necessary because ICG is a dimmer fluorophore than IRDye800, and thus a higher concentration, 500 μM (as determined from prior dose escalation studies) is used to visualize the lymph node. This increased fluorescence changes the fluorescent intensity as measured by ImageJ software. Thus, one cannot meaningfully compare the individual fluorescent intensities between each agent. Furthermore, the specific fluorescent intensities would not be able to be replicated by another user as they are specific to our unique instrumentation.) As the fluorophore cleared from the node there was an expected decrease in fluorescence intensity over time. Figure [7](#Fig7){ref-type="fig"} shows comparisons of the lymphatic clearance of (a) ICG vs. IRDye800, (b) cABD-IRDye800 vs. IRDye800, and (c) ICG vs. cABD-IRDye800. ICG had a trend of higher fluorescence intensities than IRDye800 at 15, 30, and 50 min, although only the 30 min time point reached significance while cABD-IRDye800 showed significantly higher fluorescence than IRDye800 at 30 and 50 min. ICG showed a trend similar to that of cABD-IRDye800 but did not reach significance. Statistics were performed using ANOVA and Student's *t* test with *α* = 0.05. The time points in this study were selected to determine initial baseline clearance data during an imaging session of approximately 50 min--1 h, as is typical in human clinical trials. In the preclinical studies, the \~1 h time frame allowed the anesthesia to be maintained at a low level over the study period as opposed to awakening and re-anesthetizing the animals. As it is clear from the communicated studies that IRDye800 has a statistically significantly faster clearance than the other agents, the purpose of the study was met within this time frame. Additional lymphatic clearance studies and *in vivo* whole body clearance and pharmacokinetics over longer time points may be addressed in further studies. Fig. 7Lymphatic Clearance Study: C57Bl/6 mice were injected at the base of the tail with 20 μL of 500 μM ICG or 100 μM IRDye800 or cABD-IRDye800 and imaged over several time points between 0 and 50 min to determine retention of fluorophores within the inguinal lymph node. Clearance from the node was compared between **a** ICG and IRDye800, **b** cABD-IRDye800 and IRDye800, and **c** ICG vs. cABD-IRDye800.

Discussion {#Sec15}
==========

Due to its fluorescent properties, ICG has the ability to provide fluorescence contrast for vascular imaging. However, its low quantum efficiency and instability in solution \[[@CR55]\] make ICG a poor fluorophore. Its chemical structure also limits its ability to be conjugated to targeting moieties. Consequently, other imaging agents including red excitable dyes such as Cy 5.5, and probe systems such as quantum dots have been pursued for imaging purposes, however, these agents may be limited by reduced tissue penetration, rapid vascular clearance, and/or questions on uncertain fate and toxicity. Herein, we have described the optical properties of cABD-IRDye800, a novel NIR peptide conjugate and its application in preclinical murine lymphatic imaging. *In vitro* studies confirmed the higher extinction coefficient and quantum efficiency of the IRDye800 conjugate as compared with ICG, thus showing the enhanced absorptive and fluorescence capacity provided by IRDye800. Unlike the findings of other studies \[[@CR56]\], we did not find that the extinction coefficient or quantum yield of 1 μM ICG solution increased with the addition of albumin, although it is well known that at higher solution concentrations, ICG self-quenches and the addition of albumin or aspartic acid \[[@CR57]\] can improve fluorescent yield of ICG. In addition, cABD-IRDye800 was found to be significantly more stable than ICG and maintained integrity through a 15-day study period in water and PBS at room temperature and 4°C. These results are in sharp contrast to ICG which begins to degrade within hours and at ambient temperature under normal light has a half life of only 14 h \[[@CR27]\]. More importantly at the clinically relevant excitation wavelength (\~785 nm), ICG shows an even greater reduction in stability, thereby further reducing its useful lifetime. As such the brighter and more stable cABD-IRDye800 provides an opportunity to improve upon these limitations. For further characterization of the peptide conjugate, binding assays with MSA were performed and showed that upon conjugation to IRDye800, the cABD peptide was able to maintain its specificity and affinity for albumin, thus confirming that the addition of the fluorophore did not significantly alter the binding properties of the peptide. The IC~50~ of cABD-IRDye800 for MSA was found to compare favorably to the unlabeled cABD peptide as described by Dennis *et al.* \[[@CR40]\]. In addition, the Kd of cABD-Dylight680 was in the nanomolar range again showing a high affinity of the conjugate for MSA, and consistency of the peptide once conjugated to a fluorophore. Although albumin-binding domain conjugates with higher binding affinity for albumin have been described \[[@CR45], [@CR50]\], a recent study has shown that increasing affinity beyond the nanomolar range has only minimal effects on increasing half life and that half-life extension by ABD is only weakly influenced by affinity for albumin or valency \[[@CR47]\]. As such, we have selected the peptide conjugate that provides the optimal combination of favorable properties for binding to albumin, allowing for its retention in the lymphatics, as well as for *in vivo* lymphatic imaging.

The ability of the conjugate to bind albumin and serum proteins is significant because it allows for the imaging of protein movement from the tissue space into the lymphatics. This is relevant to the present study because while the blood circulation is capable of taking up fluid and small proteins, large proteins and macromolecules can only be taken up by the large openings in the lymphatic capillaries. Therefore, when the peptide conjugate associates with these large serum proteins, it is preferentially taken up by the lymphatics. The protein association could be especially useful in monitoring diseases such as lymphedema in which impaired lymphatic flow causes an accumulation of protein in the interstitial space followed by a rise in oncotic pressure and the consequent buildup of excess fluid in the tissue, causing edema. Thus, the conjugate affords us the unique opportunity to study a key aspect of the development of edema and to assess the role of protein movement in the progression of lymphatic disease.

Although ICG is also known to associate with serum proteins, it is difficult to find direct experimental evidence that confirms this result. Therefore, we conducted studies comparing the serum binding properties of both ICG and IRDye800. We found that as expected, ICG associates with both MSA and human serum showing similar results to that of cABD-IRDye800. Despite this finding, ICG has significant limitations which include its poor optical properties and instability in solution. Also of considerable importance for use in lymphatic imaging is the ability of the fluorophore to provide bright signal imaging when injected in microdose quantities. This has significant implications for the reconstitution and use of ICG in a clinical setting to discern the presence of lymphatics. In fact, when directly comparing the stability and fluorescence of ICG and IRDye800, the latter is clearly superior and serves as a good alternative to ICG. However, clearance studies show that IRDye800 rapidly clears from the lymphatics, likely due to a reduced association to serum proteins. Therefore, we have selected the cABD-IRDye800 conjugate which allows us to maximize fluorescent yield and enhance lymphatic retention.

Interestingly, although IRDye800 did appear to associate with MSA, it did not appear to bind to human serum even though the molar concentrations and conditions for incubation were the same for ICG and IRDye800. These results indicate that IRDye800 may have a reduced affinity for or inability to bind human serum proteins and therefore may not be useful for imaging protein movement in clinical lymphatic studies.

To assess another factor that may impact binding to albumin, the partition coefficient of each fluorophore in octanol and water was measured, which provided an order of hydrophobicity for the fluorophores as cABD-IRDye800 \> ICG \> IRDye800. These results suggest that the slightly increased hydrophobicity of ICG and cABD-IRDye800 may favor their binding within the hydrophobic albumin binding pocket as compared with IRDye800 and may play some part in the increased retention time of these two agents within the lymphatics.

From these studies, there are several significant advantages to using cABD-IRDye800 for imaging lymphatics as compared with a free dye alone. First, the cABD peptide conjugate is uniquely directed to the lymphatic system due to its high affinity for albumin thereby enhancing vascular retention, as opposed to a free dye which may have a more transient interaction or be small enough to be taken up into the blood vasculature. Second, by conjugation to the bright near-infrared dye, IRDye800, the imaging agent gains a brighter fluorescent intensity, enhanced optical properties, and long term stability in solution---all necessary for imaging key structures of the lymphatics. In support of our selection of this fluorophore conjugate, a previous study \[[@CR56]\] showed that in comparison to several other NIR fluorophores including ICG, an IRDye800 conjugate of albumin had the best outcome with respect to physical properties, uptake and retention, fluorescence signal and reproducibility in sentinel lymph node mapping. Our albumin-binding domain conjugate has these favorable properties without direct conjugation at undefined sites to a bulky albumin molecule. Third, the peptide and dye are both well characterized, the conjugate is relatively small, readily synthesized and has a quantifiable 1:1 conjugation chemistry, all of which significantly enhance its ability to be used clinically.

Subsequent comparative murine imaging studies confirmed that cABD-IRDye800 shows uptake and retention in the lymphatics, as well as high sensitivity imaging at lower concentrations than ICG. These results again highlight the superior optical properties of the conjugate. The ability to use a brighter NIR fluorophore for imaging allows for the delivery of microdose quantities of the imaging agent, which not only reduces the possibility for any adverse reactions but also reduces the stringency of FDA criteria in subsequent clinical studies, thus allowing more rapid advancement of the imaging agent to the clinic. As we intend to employ NIR fluorophores for clinical use, it is also important that the fluorophore be able to remain in the lymphatics for at least 1 h during the patient imaging session, which was reflected in the time points chosen for the clearance study. Our clearance study indicated that cABD-IRDye800 and ICG were both retained in the lymph node longer than IRDye800 as determined by the comparatively higher total fluorescence in the lymph node. IRDye800 (as a free dye), was able to rapidly enter the lymphatics, but also appeared to clear very rapidly from the inguinal lymph node and had less than 30% of maximum fluorescence remaining at 50 min. The more rapid clearance of IRDye800 may be attributed to the fact that unlike ICG, which associates with albumin and serum proteins \[[@CR58]\] that may aid in lymphatic retention, IRDye800 may have a more transient or weaker association with MSA, and may not bind human serum proteins at a detectable level. This result is substantiated by the similar lymph node clearance behavior of ICG and cABD-IRDye800, which differed from that of IRDye800 alone. Thus, IRDye800 may not reflect physiological protein movement in the lymphatics as do ICG and cABD-IRDye800 and may clear too rapidly to be useful. In particular, when imaging lymphedema subjects with NIR fluorescence, it may not be warranted to intradermally inject additional fluid volume or protein into fibrotic tissue; therefore, retention of the initial microdose over the duration of the imaging session is important. Several fluorophores have been directly conjugated onto large proteins or molecules such as albumin, polyethylene glycol or hyaluronan to achieve this purpose; however, the large size of these conjugates as well as potential issues with chemistry, manufacturing and control of a large molecule, may limit their clinical applicability. As a consequence, we seek to intradermally administer the small, labeled cABD peptide for *in situ* binding of serum protein and subsequent lymphatic transit, in order to enable a diagnostic measure of protein movement. In addition, safety and toxicity studies with IRDye800 show a favorable toxicity profile \[[@CR51]\], and studies of similar ABD peptides in murine models also suggest safety and efficacy \[[@CR40]\], thus we expect future studies will confirm similar outcomes for the conjugate. We anticipate this technology will be useful in addressing the cause of patient edema, assessing treatment strategies, and evaluating specific changes in the vasculature over time. In addition, Kwon and Sevick-Muraca \[[@CR59]\] used ICG in preclinical animal models of cancer metastasis to demonstrate progressive changes in lymphatic vascular structure and transport function with advancing disease. A brighter, cABD-based agent may also be useful to better image tumor lymphangiogenesis in cancer patients. Since several emerging therapeutics against tumor lymphangiogenesis are under development, a more effective agent could be used to stratify patients who could be candidates for anti-lymphangiogenesis therapy as well as provide a metric to evaluate therapeutic response.

Conclusions {#Sec16}
===========

Based upon our collective results, cABD-IRDye800 appears to be a favorable imaging agent for lymphatic imaging studies. cABD-IRDye800 provides a unique opportunity to noninvasively image the lymphatics and to enhance our understanding of the underlying pathology of lymphatic disease for improved patient diagnosis, monitoring, and treatment. The ability to translate our imaging agent, and other subsequent vascular imaging agents into the clinic is of utmost importance as it has significant implications for improving disease management and outcome in a patient population in which there is very limited knowledge of disease pathogenesis and few treatment options. Taken together, our peptide conjugate and noninvasive NIR imaging technology have the ability to be an effective tool to begin to address the challenges of diagnosing and treating lymphatic disease. Elucidating the changes that occur in lymphatic disease will help us to further understand the complex interplay that occurs between the lymphatics, blood vasculature, and other organ systems in vascular disease, and may lead to future discoveries in related metabolic disorders such as diabetes, obesity, and cancer.
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Supplemental Fig. 1An HPLC stability study of ICG in saline over a 25-h period shows that ICG is unstable and rapidly forms degradation product. (PDF 31 kb)
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